Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx x doplňuje sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. a x. 46/2008 Xx. x. x. a xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 97/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx1).
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x xxxxxxx s xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem vstupu xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx X Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx platné xx 1. ledna 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx X x její xxxxxxx xx xxxxxxx jazyka xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx přijatá xxx 19. xxxxx 2005 v Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ KODEX
Xxxxxx xx 1. xxxxx 2013
Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx X1, X2, S4.4, S4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 a M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(XXX XXXXXXX X XXXX XXXXXX)
|
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém nebo xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, syntetické drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx xxxx zakázány.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(a) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, xxx xx s xxxxxxxx xxxxx na xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
|
Pro xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje k xxxxx, xxxxxx xxxx xxxx xxxxxxxx schopno xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx xxxx xxxxxxxxxx přirozeně.
|
X2. PEPTIDOVÉ HORMONY, XXXXXXX FAKTORY X XXXXXXXX LÁTKY
Následující xxxxx a xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (CERA), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x mužů;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx;
x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx včetně xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (např. d- x l-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx v xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu v xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx pozitivní xxxxxxxxxxx xxxxx, pokud sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx terapeutické inhalační xxxxx nižší xxx xxxx xxxxxxx maximum.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
3. Ostatní xxxxxxxxxxxxxx xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx s omezením xxxxx na ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx myostatinu, xxx xx s xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Insuliny;
x) Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx proliferátory /Peroxisome Xxxxxxxxxxxx Activated Receptor δ (PPARδ) xxxxxxxx/ (xxxx. XX 1516) x Agonisté proteinkinasové xxx aktivované XXX x součinnosti s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X OSTATNÍ MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, desmopressin, plasmaexpandery (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx s podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx felypressinu pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), triamteren x xxxxx látky s xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení s xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx je xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x té, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX X KRVÍ A XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx a xxx podobných xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např.krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx ně. Suplementace xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými způsoby.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx porušit xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx úpravu (xxxx. xxxxxxxxxx) moči, xxx xx x omezením xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx zakázány xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx zakázáno xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X XXXXXX XXXXXXXX XXX SOUTĚŽI
|
Xxxxx kategorií X0 xx X5 x X1 xx M3 xxxxxxxxx výše jsou Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx isomerů (xxxx. x- a x-) jsou xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx x případě xxxxxx místního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx stimulancia:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, p-methylamfetamin, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, metylefedrin****, methylfenidát, xxxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2013 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx xxxxx.
** Lokální xxxxxx xxxxxxxxxx (např. xxxxx, xxxx xxxxxxxx) nebo xxxx podání xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx a methylefedrin xxxx zakázány xxx xxxxxxxxxxx vyšší než 10 xxxxxxxxxx x 1 ml moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, JWH073/ x XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX ZAKÁZANÉ X XXXXXXXX SPORTECH
|
P1. XXXXXXX
Xxxxxxx (etanol) xx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx se xxxx provádět dechovou xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová hodnota xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx hodnota) xx 0.10 g/l.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x parašutismus(FAI)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (XXX)
∙ Vodní xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (FITA, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x snowboard X-xxxxx x "xxx air"
∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx následující látky:
Xxxxxxxxxx, alprenolol, atenolol, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Znění jednotlivých xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.